Thank you for sharing North.

Capt., not to impose on you but I will have to start RMDs next year and are you saying that you took the RMD in stock and deposited into a tax account? Can you do an RMD with a combination of stock and cash? TIA if you desire to disclose.

I would defer to those more knowledgeable in this area, but this AI description indicates that an AG can sometimes be used in settlements in infringement cases since you mention a possible settlement.

I think for an appreciable effect however whatever arrangement would need to incorporate the other Generic cos besides Hikma. It does unfortunately sound more like for patent litigation rather than infringement but I did see something yesterday that mentioned an AG being using in an infringement litigation. FWIW:

"AI Overview

Authorized generics (AGs) can be a source of litigation and settlement because they can impact the generic drug industry and the Hatch-Waxman Act :

Competition
AGs can increase competition for generic drugs during the 180-day exclusivity period granted to the first generic by the Hatch-Waxman Act. This can make it difficult for generic companies to recover litigation costs and reduce their potential reward for challenging patents.

Hatch-Waxman Act
AGs don't have to follow the Hatch-Waxman Act's 180-day exclusivity period, which could threaten the generic industry.

Settlement
A brand company may choose to settle patent litigation with a generic company by launching an AG. Settlements can be economically rational if the net present value of the settlement is greater than the cost of litigation for both parties. "

Actually your scenario is very upbeat and I would be thrilled if by this time next year ex-US sales were equal to US sales - assuming it is not because US sales dropped by much more than 5%.

I understand that logic but I don't know if that impacts the guilt or innocence of the offending party. One could argue that the illegal infringement was so devastating to Amarin that introducing an AG was the company trying everything it could to survive. If everything in the courts didn't move at such a glacial pace.

So we should see a more significant drop in cash next qtr right? Assuming no further payments coming in. Gotta hope for no more PBMs dropping brand V and on a hopeful note maybe Amarin can negotiate their way back onto the CvS Caremark formulary in the New Year.

I don’t know the answer but management mentions they are looking and getting ready at every PR. Maybe we get a little more info about an AG at the Investors Conference

You are correct with one caveat. Revenue went from 55m to 47m to 42m in qtr 1,2,3. The drops of course related to drops in US sales. We have to hope that no more carriers/PBMs use the CVS example to drop brand V in the future. If there is no more/much erosion then I think we are on a path (albeit a snail's pace) to a comeback.

“-- Company Remains Committed to Maintaining Public Listing –“

That worries me a little. Everyone knows why.

Obviously water under the bridge and just daydreaming, but was thinking about JL's "fast nickels over slow dimes" motto, and wondered how our trajectory would have changed if Amarin had been able to snag Germany early and right off the bat. It would have obviously required a more aggressive discount on pricing but.... fast nickels over slow dimes....

The company has been bringing down SGA expenses - albeit imho they waited too long to do so. Checked back and Q3 for 2022 the SGA was 58.7 million and the last qtr 3 months ago it was down to 38 million. The previous qtr it was 39.8 million so it could be that they are bumping up against whatever minimum is needed to operate considering they are trying to spread out worldwide. Thought just crossed my mind, that they should have let North invest their cash for them and now we would be sitting on a goldmine!

Good point JRoon.

I am not sure what you mean by a positive quarter. If you mean Net Profit, you or someone would have to show me how you fill in the other lines, because I can't see a profit unless you peg SGA and R and D at less than 23m.

Didn’t some organization or medical entity put out a protocol for treating CVD and list Colchicine as part of the treatment?

BW, it is hard for me to believe that we would see a big upside surprise to revenue or earnings. In our case it should be pretty predictable with only one product. Unless market participants didn't fully understand that the 25% predicted loss in revenue was only related to commercial plans, but I think I am reaching with that thought.

Like you, I hope I am wrong. I also hope that the expected negative earnings report does not cause a drop in stock price (priced in already hopefully) and that the Investor's Conference two weeks later focuses on some unknown good news or path forward rather than trying to resurrect a destroyed stock price.

Ramfan = Schrödinger's Cat

Capt., how about the Investor's Conference? Do you have any idea or gut feeling what that might be about? Hope it is not some pump session to try
to buoy back the stock after a disastrous ER, but with Amarin that is a worry. Hopefully, it is an opportunity to provide a little more clarity (I know they don't want to give away any secrets to help competitors or at least that is what they say) about their business decisions going forward and maybe put a little fear into the shorts and possibly get more investors interested in jumping back in on the long side.

Heck, when I saw it go negative after the opening, I bought more at 28.65.

As far as answering your last question..... I got into Amarin before Marine as I felt quite confident about my knowledge surrounding EPA. For PFE... I retired at the end of 2018 and by the Fall of 2020 had convinced my wife (boy did that take a lot of convincing especially after the DuDisaster left us smarting with our Amarin position) that to increase our income in retirement we should create a portfolio composed of dividend stocks. Oct. 2020 put that money work and PFE was one of 20 stocks chosen. But I should have dumped it when it hit over $60 at the height of the Covid vax intro. I have since purchased more at prices below $30. So I console myself with the div for the time being. With Amarin, we need a Hail Mary of some type but as MrMain and others here, have brought down cost basis over time and really would be satisfied if not thrilled by selling out at $5.

North, others, PFE beat earnings expectations handily. Not that it is boosting the stock price in any major way though. Will have to follow their developments..

Triple, I assume (could be wrong of course) that the specific day in November is still open and not set. My question is whether most are expecting Vazkepa to be on this approved list for 2025? Would Edding be first to make the announcement after NRDL releases the list?

Thanks Kiwi. I really like RZLT's CEO when I heard him talk. I think I will hang in there as well.

Thanks for posting. Fresh off the presses. Recognize many authors but one intrigues me. Tardif (University of Montreal). First job I had coming out of school was as a chemist for a small Pharma in Montreal and I worked for a guy by the name of Tardif. Of course that name is very common in the French part of Canada.

I will be ticked off (wanted to be nice) if the stock is taken down after ER and they say it is because of revenue drop related to CVS. That was divulged months ago. Often I find the market does what it wants and then they fit in whatever narrative they want.

Market up and Amarin stock price seems to be waking up as well.

Don't really know who this SanDiegoLiving is (other than he looks like Leonardo DiCaprio) but would be interested if any of our legal eagles here opine on SDL's legal viewpoints.

I think you are correct. If this story were accurate about Denner/PFE, the story would have definitely mentioned Starboard, as in….” …. Denner joining Starboard in raising concerns, blah, blah, blah….”

Thanks for posting. I was a little confused because tonight was the first that I had heard of Denner's involvement with PFE. I knew that Starboard was putting pressure, but thought when I saw the post earlier tonight that Denner was involved also. Makes sense that someone got that mixed up.

Checking Sarissa's holdings, PFE is not one of them:

https://whalewisdom.com/filer/sarissa-capital-management-lp

I likewise have fairly decent sized investments in both. I regret not selling my PFE when it hit $60 a couple of years back, but have since added quite more in the high 20’s. Mostly for the div but think this can have some capital appreciation as well. At least I have no worries of a RS with PFE.

Interesting since a short while ago another activist hedge fund, Starboard Value, built a $1 billion dollar position in PFE and is pushing for changes as well.

For anyone interested in the Investor Day virtual event. Need to register in advance:

“[II] Virtual Analyst & Investor Day 2024 – November 14 – The Company will host a virtual analyst and investor day on Thursday, November 14, 2024, from 8:00 AM EST to 10:00 AM EST. The event will be hosted by members of the Amarin senior management team and will focus on updating the investment community on the current state of the VASCEPA/VAZKEPA franchise, with particular attention given to discussions on the dynamics of key geographies that represent the future value of the franchise, including Europe. In addition, a dedicated question and answer session will be held during which the Amarin senior management team will entertain questions submitted in advance to investor.relations@amarincorp.com.
As a virtual event, the program will be webcast and archived for future reference and will be open to all participants; participation will require a simple registration step before joining, which will be available through the Company website prior to this event. Throughout the event, there will be no live interaction with audience participants.”

And, using up our SS benefits!

Do not disagree with you at all but rules on diabetes changed causing some of the increase. Used to be you had to have a blood sugar reading of over 140. Then that was lowered to 126, and now a couple of readings over 100 and the person is classified such.

I hope so. On a Yahoo Finance app I have it says avg price target is $11.65

Thanks again for that info. I guess that means that the district court doesn't do or plan anything for at least those 90 days, waiting to see if the defendant petitions the SC?

Thanks for posting. I liked the non-derogatory comment concerning RESPECT EPA:

“Most recently, the RESPECT EPA trial (Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid) investigated the effects of 1.8 g/d IPE in Japanese patients with documented coronary artery disease and a low EPA/AA ratio at baseline. This study showed a 21% reduction in major adverse cardiovascular events (hazard ratio, 0.79 [0.62–1.00]) concomitant with significant increases in both EPA levels and the EPA/AA ratio.30 Post hoc evaluation of patients in each arm who did (IPE arm) and did not (control arm) achieve increases in EPA levels showed a significant reduction in the primary end point. Together, these data suggest that targeting the EPA/AA ratio as a modifiable risk factor in ASCVD prevention warrants further investigation with IPE. By increasing EPA levels, IPE treatment may favor a balance between pro-inflammatory and pro-resolving oxylipins implicated in atheroma development to augment the other direct cardioprotective mechanisms of EPA.1”

I defer to you North. Although a number of articles I have seen use the term "suing" rather than simply FTC PRs.

https://www.npr.org/2024/09/21/nx-s1-5121886/insulin-ftc-lawsuit-pharmacy-benefit-manager

I think the other part to this odyssey has been all the other lost opportunities.

I know that some old timers like you, me, and others have been adding and bringing our cost avg down. Hopefully some newbies are in the same boat. Taking $4 or $5 today, for some of us, might be a more interesting proposition than waiting years for a significantly higher number.

LOL Ram. I actually retired at the end of 2018 (sold my business) and waited until April of 2019 to claim SS at FRA, so I am ahead of you a bit. If we could catch a break here and turn this investment around, I guess I would be satisfied with my retirement situation. And, since I am no longer paying SS taxes since all my income is either SS, cap gains, or dividends, I guess I am not helping you much. But hopefully, you don't have too much longer to wait.

Typo: It is hard “NOT” to believe that with an arrangement such as this (no brand V only GV covered) that a large percentage of those scripts are for the CVD indication and are clearly infringement on valid patents.